Marina
Restarting the trial will require the company to raise additional funds before its money runs out this summer.
The project stems from a microRNA drug and diagnostics partnership forged earlier this year.
The higher losses came amid increased costs.
Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435
NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,
Mar 13, 2014
Feb 27, 2014
Jan 16, 2014
Jan 9, 2014
Jan 2, 2014
Aug 22, 2013
Aug 15, 2013
Jun 27, 2013
May 30, 2013
May 2, 2013
Jan 31, 2013
Jan 24, 2013
Dec 13, 2012
Dec 6, 2012
Nov 15, 2012